PhaseRx Inc (NASDAQ:PZRX) posted its earnings results on Monday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.07.
PhaseRx (NASDAQ:PZRX) opened at 1.486 on Tuesday. The firm’s market capitalization is $17.37 million. The stock’s 50 day moving average price is $1.60 and its 200 day moving average price is $1.71. PhaseRx has a 52-week low of $0.96 and a 52-week high of $5.77.
PhaseRx Company Profile
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Ratings for PhaseRx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc and related companies with MarketBeat.com's FREE daily email newsletter.